David Davidson’s R&D odyssey takes him out of bluebird to another biotech startup with big plans to transform therapy

John Carroll

Editor & Founder

David Davidson’s nearly decade-long stretch as the chief medical officer at bluebird bio ran the full gamut of drug hunting events: Remarkable scientific pioneering and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

David Davidson’s R&D odyssey takes him out of bluebird to another biotech startup with big plans to transform therapy

John Carroll

Editor & Founder

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Amgen announces hold on Phase 1 obesity candidate, pipeline cuts

Bristol Myers, Kyowa Kirin disclose layoffs

EyePoint shares more mid-stage data for therapy trying to compete with Regeneron's Eylea

Pfizer says it has at least $10B available for deals in 2025, with a focus on pipeline

GSK defiant against vaccine challenges, will prioritize other growth areas

With first drug now in the clinic, Alys eyes megaround for rest of pipeline

David David­son’s R&D odyssey takes him out of blue­bird to an­oth­er biotech start­up with big plans to trans­form ther­a­py

Editor & Founder

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

David Davidson’s R&D odyssey takes him out of bluebird to another biotech startup with big plans to transform therapy